Biomarkers for therapy selection in metastatic urothelial cancer

Abstract

The treatment of metastatic urothelial cancer (mUC) has been transformed by recent progress in clinical trials and drug development. There are now three therapeutic classes with proven benefits in mUC: chemotherapy, immunotherapy, and targeted therapy. The optimal sequence and combination of these classes remain to be defined. Biomarker development is essential to guide treatment selection at each therapeutic juncture. Two biomarkers, programmed death-ligand 1 expression and fibroblast growth factor receptor alterations, have been incorporated into the mUC treatment paradigm thus far. This review discusses predictive biomarkers in development and their potential to influence mUC treatment selection moving forward.

Keywords

Metastatic urothelial cancer / biomarkers / immunotherapy / chemotherapy / targeted therapy / antibody-drug conjugates

References

[1] Bellmunt J,Demkov T.Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.J Clin Oncol2009;27:4454-61

[2] Powles T,Voog E.Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma.N Engl J Med2020;383:1218-30

[3] Bellmunt J,Vaughn DJ.KEYNOTE-045 InvestigatorsPembrolizumab as second-line therapy for advanced urothelial carcinoma.N Engl J Med2017;376:1015-26 PMCID:PMC5635424

[4] Powles T,Sonpavde GP.Enfortumab vedotin in previously treated advanced urothelial carcinoma.N Engl J Med2021;384:1125-35 PMCID:PMC8450892

[5] Tagawa ST,Petrylak DP.TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors.J Clin Oncol2021;39:2474-85 PMCID:PMC8315301

[6] Loriot Y,Petrylak D.LBA24 TROPHY-U-01 cohort 1 final results: a phase II study of sacituzumab govitecan (SG) in metastatic urothelial cancer (mUC) that has progressed after platinum (PLT) and checkpoint inhibitors (CPI).Ann Oncol2020;31:S1156

[7] Loriot Y,Park SH.BLC2001 Study GroupErdafitinib in locally advanced or metastatic urothelial carcinoma.N Engl J Med2019;381:338-48

[8] Loehrer PJ Sr,Elson PJ.A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.J Clin Oncol1992;10:1066-73

[9] Logothetis CJ,Finn L.A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.J Clin Oncol1990;8:1050-5

[10] von der Maase H,Roberts JT.Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.J Clin Oncol2000;18:3068-77

[11] Galsky MD,Bamias A.Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.Lancet2020;395:1547-57

[12] Powles T,Özgüroğlu M.Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.Lancet Oncol2021;22:931-45

[13] Powles T,Castellano D.Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.Lancet Oncol2020;21:1574-88

[14] Rosenberg JE,Friedlander TW.Study EV-103: durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.J Clin Oncol2020;38:5044

[15] Li X.Homologous recombination in DNA repair and DNA damage tolerance.Cell Res2008;18:99-113 PMCID:PMC3087377

[16] Reardon JT,Chaney SG.Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.Cancer Res1999;59:3968-71

[17] Lord RVN,Gandara D.Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.Clin Cancer Res2002;8:2286-91

[18] Britten RA,Tessier A,Murray D.ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells.Int J Cancer2000;89:453-7

[19] Olaussen KA,Fouret P.IALT Bio InvestigatorsDNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.N Engl J Med2006;355:983-91

[20] Dabholkar M,Bostick-Bruton F,Reed E.Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.J Clin Invest1994;94:703-8 PMCID:PMC296149

[21] Metzger R,Danenberg KD.ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.J Clin Oncol1998;16:309-16

[22] Shirota Y,Brabender J.ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.J Clin Oncol2001;19:4298-304

[23] Klatte T,Rink M.ERCC1 as a prognostic and predictive biomarker for urothelial carcinoma of the bladder following radical cystectomy.J Urol2015;194:1456-62

[24] Necchi A,Raggi D.Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: an open-label, single-arm, single-center, phase 2 study.Urol Oncol2018;36:8.e1-8

[25] Hemdan T,Malmström P.122 ERCC1-negative tumors benefit from neoadjuvant cisplatin-based chemotherapy whereas patients with ERCC1-positive tumors do not - results from a cystectomy trial database.Eur Urol2014;13:e122

[26] Choueiri TK,Bellmunt J.Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.J Clin Oncol2014;32:1889-94 PMCID:PMC7057274

[27] Sakano S,Yamamoto Y.ERCC1 and XRCC1 expression predicts survival in bladder cancer patients receiving combined trimodality therapy.Mol Clin Oncol2013;1:403-10 PMCID:PMC3916156

[28] Sun JM,Park SH.ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy.BMC Cancer2012;12:187 PMCID:PMC3404914

[29] Kawashima A,Kawamura N.Co-expression of ERCC1 and Snail is a prognostic but not predictive factor of cisplatin-based neoadjuvant chemotherapy for bladder cancer.Oncol Lett2012;4:15-21

[30] Ozcan MF,Dincer N.Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy.Urol Oncol2013;31:1709-15

[31] Nikitas N,Tsitoura E.Association of ERCC1 SNPs with outcome in platinum-treated patients with advanced urothelial cancer: a Hellenic Cooperative Oncology Group study.Pharmacogenomics2012;13:1595-607

[32] Kim KH,Kim HS.Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy.APMIS2010;118:941-8

[33] Hoffmann AC,Leicht C.MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.Neoplasia2010;12:628-36 PMCID:PMC2915407

[34] Bellmunt J,Cuello M.Spanish Oncology Genitourinary GroupGene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.Ann Oncol2007;18:522-8

[35] Urun Y,Fay AP,Choueiri TK.ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: a systematic review and meta-analysis.Crit Rev Oncol Hematol2017;120:120-6

[36] Robertson AG,Al-Ahmadie H.TCGA Research NetworkComprehensive molecular characterization of muscle-invasive bladder cancer.Cell2017;171:540-56.e25 PMCID:PMC5687509

[37] Li Q,Frazier Z.ERCC2 helicase domain mutations confer nucleotide excision repair deficiency and drive cisplatin sensitivity in muscle-invasive bladder cancer.Clin Cancer Res2019;25:977-88 PMCID:PMC6434536

[38] Van Allen EM,Kim P.Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.Cancer Discov2014;4:1140-53 PMCID:PMC4238969

[39] Liu D,Hoffman-Censits J.Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma.JAMA Oncol2016;2:1094-6 PMCID:PMC5515075

[40] Christensen E,Sethi H.Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma.J Clin Oncol2019;37:1547-57

[41] Groenendijk FH,Fransen van de Putte EE.ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy.Eur Urol2016;69:384-8

[42] Groenendijk FH,van Rhijn BW,van der Heijden MS.Reply to Eliezer M. Van Allen, Levi A. Garraway and Jonathan E. Rosenberg's Letter to the Editor re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014.Eur Urol2015;68:e33-4

[43] Taber A,Lamy P.Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis.Nat Commun2020;11:4858 PMCID:PMC7519650

[44] Kim J,Polak P.Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors.Nat Genet2016;48:600-6 PMCID:PMC4936490

[45] Galsky MD,Chan KG.Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU 16-257.J Clin Oncol2021;39:4503

[46] Yang D,Sun Y.Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.JAMA2011;306:1557-65 PMCID:PMC4159096

[47] Sakai W,Karlan BY.Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.Nature2008;451:1116-20 PMCID:PMC2577037

[48] Tutt A,Cheang MCU.Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.Nat Med2018;24:628-37 PMCID:PMC6372067

[49] Carlo MI,Srinavasan P.Cancer susceptibility mutations in patients with urothelial malignancies.J Clin Oncol2020;38:406-14 PMCID:PMC7351337

[50] Nassar AH,AlDubayan SH.Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma.Genet Med2020;22:709-18 PMCID:PMC7118025

[51] Mullane SA,Guancial EA.Expression levels of DNA damage repair proteins are associated with overall survival in platinum-treated advanced urothelial carcinoma.Clin Genitourin Cancer2016;14:352-9 PMCID:PMC5508512

[52] Lord CJ.RAD51, BRCA2 and DNA repair: a partial resolution.Nat Struct Mol Biol2007;14:461-2

[53] Plimack ER,Brennan TA.Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer.Eur Urol2015;68:959-67 PMCID:PMC4764095

[54] Miron B,Anari F.Defects in DNA repair genes and long-term survival in cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer (MIBC).J Clin Oncol2019;37:4536-4536

[55] Teo MY,Zabor EC.DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma.Clin Cancer Res2017;23:3610-8 PMCID:PMC5511570

[56] Blaveri E,Korkola JE.Bladder cancer outcome and subtype classification by gene expression.Clin Cancer Res2005;11:4044-55

[57] Dyrskjøt L,Kruhøffer M.Identifying distinct classes of bladder carcinoma using microarrays.Nat Genet2003;33:90-6

[58] Lindgren D,Gudjonsson S.Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome.Cancer Res2010;70:3463-72

[59] Sjödahl G,Lövgren K.A molecular taxonomy for urothelial carcinoma.Clin Cancer Res2012;18:3377-86

[60] Volkmer JP,Chin RK.Three differentiation states risk-stratify bladder cancer into distinct subtypes.Proc Natl Acad Sci U S A2012;109:2078-83 PMCID:PMC3277552

[61] Tan TZ,Tan KT,Thiery JP.Molecular subtypes of urothelial bladder cancer: results from a meta-cohort analysis of 2411 tumors.Eur Urol2019;75:423-32

[62] Hurst CD,Platt FM.Genomic subtypes of non-invasive bladder cancer with distinct metabolic profile and female gender bias in KDM6A mutation frequency.Cancer Cell2017;32:701-15.e7 PMCID:PMC5774674

[63] Hedegaard J,Nordentoft I.Comprehensive transcriptional analysis of early-stage urothelial carcinoma.Cancer Cell2016;30:27-42

[64] Choi W,Kim S.Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.Cancer Cell2014;25:152-65 PMCID:PMC4011497

[65] Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma.Nature2014;507:315-22

[66] Mo Q,Chen F.Prognostic power of a tumor differentiation gene signature for bladder urothelial carcinomas.J Natl Cancer Inst2018;110:448-59 PMCID:PMC6279371

[67] Sjödahl G,Liedberg F.Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification.J Pathol2017;242:113-25 PMCID:PMC5413843

[68] Marzouka NA,Rovira C,Sjödahl G.A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort.Sci Rep2018;8:3737 PMCID:PMC5829240

[69] Rebouissou S,de Reyniès A.EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype.Sci Transl Med2014;6:244ra91

[70] Damrauer JS,Chism DD.Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology.Proc Natl Acad Sci U S A2014;111:3110-5 PMCID:PMC3939870

[71] Kamoun A,Allory Y.Bladder Cancer Molecular Taxonomy GroupA consensus molecular classification of muscle-invasive bladder cancer.Eur Urol2020;77:420-33 PMCID:PMC7690647

[72] McConkey DJ,Shen Y.A prognostic gene expression signature in the molecular classification of chemotherapy-naïve urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: a phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer.Eur Urol2016;69:855-62 PMCID:PMC4775435

[73] Seiler R,Erho N.Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy.Eur Urol2017;72:544-54

[74] Smith SC,Lee JK.The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer.Cancer Res2010;70:1753-8 PMCID:PMC2831138

[75] Flaig TW,Daneshmand S.A randomized phase II study of coexpression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer (SWOG S1314; NCT02177695).Clin Cancer Res2021;27:2435-41 PMCID:PMC8219246

[76] Rosenberg JE,Halabi S.CALGB 90601 (Alliance): randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma.J Clin Oncol2019;37:4503

[77] National Cancer Institute (NCI). A randomized double-blinded phase III study comparing gemcitabine, cisplatin, and bevacizumab to gemcitabine, cisplatin, and placebo in patients with advanced transitional cell carcinoma. Available from: https://clinicaltrials.gov/ct2/show/NCT00942331 [Last accessed on 11 Jan 2022]

[78] Geynisman DM,Ross EA.A phase II trial of risk enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN BLADDER): interim analysis.J Clin Oncol2021;39:397

[79] Rosenberg JE,Powles T.Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.Lancet2016;387:1909-20 PMCID:PMC5480242

[80] Balar AV,Rosenberg JE.Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.Lancet2017;389:67-76 PMCID:PMC5568632

[81] Sharma P,Siefker-radtke A.Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.Lancet Oncol2017;18:312-22

[82] Balar AV,O'donnell PH.First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.Lancet Oncol2017;18:1483-92

[83] Powles T,Massard C.Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 Open-label study.JAMA Oncol2017;3:e172411 PMCID:PMC5824288

[84] Patel MR,Infante JR.Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.Lancet Oncol2018;19:51-64 PMCID:PMC7984727

[85] Grivas P,Voog E.Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): analysis of time to end of next-line therapy in JAVELIN Bladder 100.J Clin Oncol2021;39:4525

[86] Powles T,Bellmunt J.699O avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): association between clinical outcomes and exploratory biomarkers.Ann Oncol2020;31:S552-3

[87] Powles T,Davarpanah N.ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.Nature2021;595:432-7

[88] Bellmunt J,Gschwend JE.Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol2021;22:525-37 PMCID:PMC8495594

[89] Wang L,Saci A.Fibroblast growth factor receptor 3 alterations and response to PD-1/PD-L1 blockade in patients with metastatic urothelial cancer.Eur Urol2019;76:599-603 PMCID:PMC6801024

[90] Rose TL,Mayhew GM.Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience.Br J Cancer2021;125:1251-60 PMCID:PMC8548561

[91] Powles T,Chowdhury S.An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer.Nat Med2021;27:793-801

[92] FDA alerts health care professionals and oncology clinical investigators about an efficacy issue identified in clinical trials for some patients taking keytruda (pembrolizumab) or tecentriq (atezolizumab) as monotherapy to treat urothelial cancer with low expression of PD-L1. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerts-health-care-professionals-and-oncology-clinical-investigators-about-efficacy-issue [Last accessed on 11 Jan 2022]

[93] Galsky MD,Sridhar SS.A phase III, randomized, open-label, multicenter, global study of first-line durvalumab plus standard of care (SoC) chemotherapy and durvalumab plus tremelimumab, and SoC chemotherapy versus SoC chemotherapy alone in unresectable locally advanced or metastatic urothelial cancer (NILE).J Clin Oncol2021;39:TPS504

[94] Rui X,Pan HF.Evaluation of PD-L1 biomarker for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatments for urothelial carcinoma patients: a meta-analysis.Int Immunopharmacol2019;67:378-85

[95] Litchfield K,Puttick C.Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition.Cell2021;184:596-614.e14 PMCID:PMC7933824

[96] Powles T,van der Heijden MS.Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.Lancet2018;391:748-57

[97] Hirsch FR,Stanforth D.PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project.J Thorac Oncol2017;12:208-22

[98] Ratcliffe MJ,Midha A.Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer.Clin Cancer Res2017;23:3585-91

[99] Tsao MS,Kockx M.PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project.J Thorac Oncol2018;13:1302-11 PMCID:PMC8386299

[100] Decazes P.Immunotherapy by immune checkpoint inhibitors and nuclear medicine imaging: current and future applications.Cancers (Basel)2020;12:371 PMCID:PMC7072145

[101] Bensch F,Lub-de Hooge MN.⁸⁹Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer.Nat Med2018;24:1852-8

[102] Niemeijer AN,Huisman MC.Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer.Nat Commun2018;9:4664 PMCID:PMC6220188

[103] Alexandrov LB,Wedge DC.Australian Pancreatic Cancer Genome Initiative, ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, ICGC PedBrainSignatures of mutational processes in human cancer.Nature2013;500:415-21 PMCID:PMC3776390

[104] Samstein RM,Shoushtari AN.Tumor mutational load predicts survival after immunotherapy across multiple cancer types.Nat Genet2019;51:202-6 PMCID:PMC6365097

[105] Mariathasan S,Nickles D.TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.Nature2018;554:544-8 PMCID:PMC6028240

[106] Bellmunt J,Fradet Y.747P association of TMB with efficacy of pembrolizumab (pembro) in patients (pts) with advanced urothelial cancer (UC): results from KEYNOTE-045 and KEYNOTE-052.Ann Oncol2020;31:S580-1

[107] FDA approves pembrolizumab for adults and children with TMB-H solid tumors. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors [Last accessed on 11 Jan 2022]

[108] Yarchoan M,Hopkins AC.PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers.JCI Insight2019;4:126908 PMCID:PMC6482991

[109] Galsky MD,Szabo PM.Nivolumab in patients with advanced platinum-resistant urothelial carcinoma: efficacy, safety, and biomarker analyses with extended follow-up from checkmate 275.Clin Cancer Res2020;26:5120-8 PMCID:PMC8166422

[110] Galsky MD,Hamidi HR.Tumor, immune, and stromal characteristics associated with clinical outcomes with atezolizumab (atezo) + platinum-based chemotherapy (PBC) or atezo monotherapy (mono) versus PBC in metastatic urothelial cancer (mUC) from the phase III IMvigor130 study.J Clin Oncol2020;38:5011

[111] Valero C,Hoen D.Response rates to anti-PD-1 Immunotherapy in microsatellite-stable solid tumors with 10 or more mutations per megabase.JAMA Oncol2021;7:739-43 PMCID:PMC7893543

[112] Vokes NI,Ricciuti B.Harmonization of tumor mutational burden quantification and association with response to immune checkpoint blockade in non-small-cell lung cancer.JCO Precis Oncol2019;3:1-12 PMCID:PMC6907021

[113] Mandal R,Lee KW.Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response.Science2019;364:485-91 PMCID:PMC6685207

[114] McGranahan N,Hiley CT.TRACERx ConsortiumAllele-specific HLA loss and immune escape in lung cancer evolution.Cell2017;171:1259-71.e11 PMCID:PMC5720478

[115] Wang CY,Korneluk RG,Baldwin AS Jr.NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation.Science1998;281:1680-3

[116] Vredevoogd DW,Ligtenberg MA.Augmenting immunotherapy impact by lowering tumor TNF cytotoxicity threshold.Cell2019;178:585-99.e15

[117] Zhang J,Wang H.Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance.Nature2018;553:91-5 PMCID:PMC5754234

[118] O'donnell PH,Balar AV.Biomarker findings and mature clinical results from KEYNOTE-052: first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC).J Clin Oncol2017;35:4502

[119] Wang L,Szabo PM.EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer.Nat Commun2018;9:3503 PMCID:PMC6115401

[120] Calon A,Berenguer-Llergo A.Stromal gene expression defines poor-prognosis subtypes in colorectal cancer.Nat Genet2015;47:320-9

[121] Massagué J.TGFbeta in cancer.Cell2008;134:215-30 PMCID:PMC3512574

[122] Lin RL.Mechanistic basis and clinical relevance of the role of transforming growth factor-β in cancer.Cancer Biol Med2015;12:385-93 PMCID:PMC4706525

[123] Powles T,Park SH.Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial.J Clin Oncol2021;39:4520

[124] Binnewies M,Kersten K.Understanding the tumor immune microenvironment (TIME) for effective therapy.Nat Med2018;24:541-50 PMCID:PMC5998822

[125] Chen DS.Oncology meets immunology: the cancer-immunity cycle.Immunity2013;39:1-10

[126] Herbst RS,Kowanetz M.Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.Nature2014;515:563-7 PMCID:PMC4836193

[127] Chen B,Liu CL,Alizadeh AA.Profiling Tumor Infiltrating Immune Cells with CIBERSORT.Methods Mol Biol2018;1711:243-59 PMCID:PMC5895181

[128] Aran D,Butte AJ.xCell: digitally portraying the tissue cellular heterogeneity landscape.Genome Biol2017;18:220 PMCID:PMC5688663

[129] Cao J,Li J.Screening and identifying immune-related cells and genes in the tumor microenvironment of bladder urothelial carcinoma: based on TCGA database and bioinformatics.Front Oncol2019;9:1533 PMCID:PMC6974676

[130] Gohil SH,Braun DA,Livak KJ.Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy.Nat Rev Clin Oncol2021;18:244-56 PMCID:PMC8415132

[131] Guruprasad P,Kim KH.The current landscape of single-cell transcriptomics for cancer immunotherapy.J Exp Med2021;218:e20201574 PMCID:PMC7754680

[132] Oh DY,Raju SS.Intratumoral CD4⁺ T cells mediate anti-tumor cytotoxicity in human bladder cancer.Cell2020;181:1612-25.e13 PMCID:PMC7321885

[133] Chen Z,Liu L.Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma.Nat Commun2020;11:5077 PMCID:PMC7545162

[134] Sfakianos JP,Hu Y.Epithelial plasticity can generate multi-lineage phenotypes in human and murine bladder cancers.Nat Commun2020;11:2540 PMCID:PMC7242345

[135] Mota JM,Souza LE.Post-sepsis state induces tumor-associated macrophage accumulation through CXCR4/CXCL12 and favors tumor progression in mice.Cancer Immunol Res2016;4:312-22

[136] Wang L,Beaumont KG.Myeloid cell-associated resistance to PD-1/PD-L1 blockade in urothelial cancer revealed through bulk and single-cell RNA sequencing.Clin Cancer Res2021;27:4287-300 PMCID:PMC8338756

[137] Siefker-radtke AO,Park SH.BLC2001 Study GroupERDAFITINIB in locally advanced or metastatic urothelial carcinoma (mUC): long-term outcomes in BLC2001.J Clin Oncol2020;38:5015

[138] Challita-Eid PM,Yang P.Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models.Cancer Res2016;76:3003-13

[139] Doronina SO,Torgov MY.Development of potent monoclonal antibody auristatin conjugates for cancer therapy.Nat Biotechnol2003;21:778-84

[140] Mathijssen RH,Verweij J.Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).Clin Cancer Res2001;7:2182-94

[141] Itoh N.Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease.J Biochem2011;149:121-30 PMCID:PMC3106964

[142] Plotnikov AN,Hubbard SR.Structural basis for FGF receptor dimerization and activation.Cell1999;98:641-50

[143] Dieci MV,Andre F.Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives.Cancer Discov2013;3:264-79

[144] Tomlinson DC,Harnden P.FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer.J Pathol2007;213:91-8 PMCID:PMC2443273

[145] di Martino E, Tomlinson DC, Knowles MA. A decade of FGF receptor research in bladder cancer: past, present, and future challenges.Adv Urol2012;2012:429213 PMCID:PMC3415141

[146] Helsten T,Arthur E,Carter J.The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing.Clin Cancer Res2016;22:259-67

[147] Costa R,Taxter T.FGFR3-TACC3 fusion in solid tumors: mini review.Oncotarget2016;7:55924-38 PMCID:PMC5342462

[148] Siefker-radtke A,Siena S.752P Updated data from the NORSE trial of erdafitinib (ERDA) plus cetrelimab (CET) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and specific fibroblast growth factor receptor (FGFR) alterations.Ann Oncol2020;31:S584-5

[149] Pal SK,Hoffman-Censits JH.Efficacy of BGJ398, a fibroblast growth factor receptor 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations.Cancer Discov2018;8:812-21 PMCID:PMC6716598

[150] Bellmunt J,Kohli M.FIERCE-21: Phase 1b/2 study of docetaxel + b-701, a selective inhibitor of FGFR3, in relapsed or refractory (R/R) metastatic urothelial carcinoma (mUCC).J Clin Oncol2018;36:4534

[151] Necchi A,Mellado B.Fierce-21: Phase II study of vofatmab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC).J Clin Oncol2019;37:409

[152] Siefker-radtke AO,Abella E.FIERCE-22: clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis.J Clin Oncol2019;37:4511

[153] Abdul-karim RM,Patrikidou A.Derazantinib (DZB) in combination with atezolizumab (AZB) in patients with solid tumors: results from the dose-finding phase Ib substudy of FIDES-02.J Clin Oncol2021;39:437

[154] Chaudhry A,De Santis M.FIDES-02, a phase Ib/II study of derazantinib (DZB) as monotherapy and combination therapy with atezolizumab (A) in patients with surgically unresectable or metastaticurothelial cancer (UC) and FGFR genetic aberrations.J Clin Oncol2020;38:TPS590-TPS590

[155] Hyman DM,Grivas P.FUZE clinical trial: a phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of tumor histology.J Clin Oncol2019;37:TPS3157

[156] Meric-Bernstam F,Tran B.Abstract CT238: TAS-120 in patients with advanced solid tumors bearing FGF/FGFR aberrations: a phase I study.Cancer Res2019;79:CT238

[157] Milowsky MI,Durán I.Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.Eur J Cancer2014;50:3145-52

[158] Quinn DI,Bellmunt J.FORT-1: phase II/III study of rogaratinib versus chemotherapy (CT) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) selected based on FGFR1/3 mRNA expression.J Clin Oncol2020;38:489

[159] Rosenberg JE,Morales-barrera R.Safety and preliminary efficacy of rogaratinib in combination with atezolizumab in a phase Ib/II study (FORT-2) of first-line treatment in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression.J Clin Oncol2020;38:5014

[160] Yue S,Chen X.FGFR-TKI resistance in cancer: current status and perspectives.J Hematol Oncol2021;14:23 PMCID:PMC7876795

[161] Guagnano V,Spanka C.Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.J Med Chem2011;54:7066-83

[162] Goyal L,Liu LY.Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma.Cancer Discov2017;7:252-63 PMCID:PMC5433349

[163] Datta J,Parks H.Akt activation mediates acquired resistance to fibroblast growth factor receptor inhibitor BGJ398.Mol Cancer Ther2017;16:614-24 PMCID:PMC5539948

[164] Wang L,Leite de Oliveira R.A functional genetic screen identifies the phosphoinositide 3-kinase pathway as a determinant of resistance to fibroblast growth factor receptor inhibitors in FGFR mutant urothelial cell carcinoma.Eur Urol2017;71:858-62

[165] Ryan MR,Luo B.The FGFR1 V561M gatekeeper mutation drives AZD4547 resistance through STAT3 activation and EMT.Mol Cancer Res2019;17:532-43 PMCID:PMC6647014

[166] Mandai K,Mori M.Nectins and nectin-like molecules in development and disease.Curr Top Dev Biol2015;112:197-231,

[167] Rosenberg J,Zhang J.EV-101: a phase i study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma.J Clin Oncol2020;38:1041-9 PMCID:PMC7106979

[168] Chu CE,Egusa EA.Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin.Clin Cancer Res2021;27:5123-30 PMCID:PMC8634828

[169] Hoffman-Censits JH,Parimi V.Expression of nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes.Appl Immunohistochem Mol Morphol2021;29:619-25 PMCID:PMC8429050

[170] Hoimes CJ,Petrylak DP.Study EV-103: new cohorts testing enfortumab vedotin alone or in combination with pembrolizumab in muscle invasive urothelial cancer.J Clin Oncol2020;38:TPS595

[171] Rosenberg JE,Friedlander TW.Study EV-103: preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.J Clin Oncol2020;38:441

[172] Rapani E,Corda D.Human TROP-2 is a tumor-associated calcium signal transducer.Int J Cancer1998;76:671-6

[173] Faltas B,Ocean AJ.Sacituzumab govitecan, a novel antibody--drug conjugate, in patients with metastatic platinum-resistant urothelial carcinoma.Clin Genitourin Cancer2016;14:e75-9

[174] Zhang L,Jiang H.TROP2 is associated with the recurrence of patients with non-muscle invasive bladder cancer.Int J Clin Exp Med2017;10:1643-50

[175] Wang X,Dong K.Chemotherapy agents-induced immunoresistance in lung cancer cells could be reversed by trop-2 inhibition in vitro and in vivo by interaction with MAPK signaling pathway.Cancer Biol Ther2013;14:1123-32 PMCID:PMC3912035

[176] Guerra E,Tripaldi R.Trop-2 induces tumor growth through AKT and determines sensitivity to AKT inhibitors.Clin Cancer Res2016;22:4197-205

[177] Vidula N,Rugo HS.Trop2 gene expression (Trop2e) in primary breast cancer (BC): correlations with clinical and tumor characteristics.J Clin Oncol2017;35:1075

[178] Hurvitz SA,Punie K.Abstract GS3-06: biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.Cancer Res2021;81:GS3-6

[179] Grivas P,Bellmunt J.TROPiCS-04: study of sacituzumab govitecan in metastatic or locally advanced unresectable urothelial cancer that has progressed after platinum and checkpoint inhibitor therapy.J Clin Oncol2021;39:TPS498

[180] Drakaki A,Lee J.Phase Ib/II umbrella trial to evaluate the safety and efficacy of multiple 2L cancer immunotherapy (CIT) combinations in advanced/metastatic urothelial carcinoma (mUC): MORPHEUS-mUC.J Clin Oncol2020;38:TPS591

[181] Iqbal N.Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications.Mol Biol Int2014;2014:852748 PMCID:PMC4170925

[182] Coogan CL,Kapur S.HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder.Urology2004;63:786-90

[183] Latif Z,Dunn I,Underwood MA.HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder.Br J Cancer2003;89:1305-9 PMCID:PMC2394319

[184] Hussain MH,Petrylak DP.National Cancer InstituteTrastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial.J Clin Oncol2007;25:2218-24

[185] Oudard S,Vano Y.Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2.Eur J Cancer2015;51:45-54

[186] Powles T,Elliott T.Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2-positive metastatic bladder cancer.J Clin Oncol2017;35:48-55

[187] Choudhury NJ,Antic T.Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations.J Clin Oncol2016;34:2165-71 PMCID:PMC5569685

[188] Font Pous A,Castellano DE.Phase II trial of afatinib in patients with advanced/metastatic urothelial carcinoma (UC) with genetic alterations in ERBB receptors 1-3 who failed on platinum-based chemotherapy (CT).J Clin Oncol2018;36:TPS540-TPS540

[189] Hainsworth JD,Swanton C.Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study.J Clin Oncol2018;36:536-42

[190] Sheng X,Yao X.A phase II study of RC48-ADC in HER2-positive patients with locally advanced or metastatic urothelial carcinoma.J Clin Oncol2019;37:4509

[191] Li BT,Buonocore DJ.A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers.J Clin Oncol2018;36:2502

[192] Duan Y,Yang Z.Therapeutic potential of PI3K/AKT/mTOR pathway in gastrointestinal stromal tumors: rationale and progress.Cancers (Basel)2020;12:2972 PMCID:PMC7602170

[193] Sathe A.Targeting the PI3K/AKT/mTOR pathway in bladder cancer.Methods Mol Biol2018;1655:335-50,

[194] Iyer G,Schultz N.Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer.J Clin Oncol2013;31:3133-40 PMCID:PMC3753703

[195] Platt FM,Taylor CF,Harnden P.Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer.Clin Cancer Res2009;15:6008-17

[196] Calderaro J,de Koning L.PI3K/AKT pathway activation in bladder carcinogenesis.Int J Cancer2014;134:1776-84

[197] Cappellen D,Chopin D,Radvanyi F.Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder.Oncogene1997;14:3059-66

[198] Aveyard JS,Habuchi T.Somatic mutation of PTEN in bladder carcinoma.Br J Cancer1999;80:904-8 PMCID:PMC2362287

[199] Tsuruta H,Sasaki T.Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients.Cancer Res2006;66:8389-96

[200] Knowles MA,Kennedy W.Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder.Cancer Res2003;63:7652-6

[201] Milowsky MI,Regazzi AM.Phase II study of everolimus in metastatic urothelial cancer.BJU Int2013;112:462-70 PMCID:PMC4020005

[202] Bellmunt J,Jacobus S.Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma.Br J Cancer2018;119:707-12 PMCID:PMC6173710

[203] Wagle N,Van Allen EM.Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.Cancer Discov2014;4:546-53 PMCID:PMC4122326

[204] Kim JW,Hahn NM.Sapanisertib, a dual mTORC1/2 inhibitor, for TSC1- or TSC2- mutated metastatic urothelial carcinoma (mUC).J Clin Oncol2021;39:431

[205] McPherson V,Bhayankara A.A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma.Cancer2020;126:4532-44 PMCID:PMC8356147

[206] Flaherty KT,Chen AP.NCI-MATCH teamMolecular landscape and actionable alterations in a genomically guided cancer clinical trial: national cancer institute molecular analysis for therapy choice (NCI-MATCH).J Clin Oncol2020;38:3883-94 PMCID:PMC7676882

[207] Sathe A,Cronauer MV.Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy.Br J Cancer2014;111:2103-13 PMCID:PMC4260039

[208] Dickstein RJ,Dinney CP,Kamat AM.Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells.Cancer Biol Ther2012;13:1325-38 PMCID:PMC3493441

[209] Seront E,Filleul B.Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma.BJU Int2016;118:408-15

[210] Munster P,Hong D.First-in-human phase I study of GSK2126458, an oral pan-class I phosphatidylinositol-3-kinase inhibitor, in patients with advanced solid tumor malignancies.Clin Cancer Res2016;22:1932-9

[211] Sachdev E,Roy V,Mita MM.PARP inhibition in cancer: an update on clinical development.Target Oncol2019;14:657-79

[212] Grivas P,Feyerabend S.Rucaparib for recurrent, locally advanced, or metastatic urothelial carcinoma (mUC): results from ATLAS, a phase II open-label trial.J Clin Oncol2020;38:440

[213] Apolo AB,Tomita Y.Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial.Lancet Oncol2020;21:1099-109 PMCID:PMC8236112

[214] Apolo AB,Girardi DM.Phase I study of cabozantinib and nivolumab alone or with ipilimumab for advanced or metastatic urothelial carcinoma and other genitourinary tumors.J Clin Oncol2020;38:3672-84

[215] Necchi A,Raggi D.Cabozantinib (CABO) plus durvalumab (DURVA) in patients with advanced and chemotherapy-treated bladder carcinoma of urothelial and non-urothelial histology: an open-label, single-arm, phase 2 trial.J Clin Oncol2018;36:TPS536

[216] Pal SK,Castellano DE.Phase Ib (COSMIC-021) trial of cabozantinib (C) in urothelial carcinoma (UC) or C in combination with atezolizumab (A) in patients (pts) with UC, castrate resistant prostate cancer (CRPC) or renal cell carcinoma (RCC).J Clin Oncol2019;37:TPS683

[217] Petrylak DP,Chi KN.Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.Lancet Oncol2020;21:105-20 PMCID:PMC6946880

[218] Msaouel P,Sweis R.705MO Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC).Ann Oncol2020;31:S556

[219] Cobain EF,Vats P.Assessment of clinical benefit of integrative genomic profiling in advanced solid tumors.JAMA Oncol2021;7:525-33 PMCID:PMC7907987

[220] Tomlins SA,Suga JM.Real-world performance of a comprehensive genomic profiling test optimized for small tumor samples.J Clin Oncol Precis Oncol2021;5:1312-4 PMCID:PMC8384401